Brief: Aurobindo Pharma Says FDA Classifies Eugia Unit-III Inspection As Official Action Indicated
12/06/2026 14:29
BRIEF-Aurobindo Pharma Says FDA Classifies Eugia Unit-III Inspection As Official Action Indicated June 12 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - FDA CLASSIFIES EUGIA UNIT-III INSPECTION AS OFFICIAL ACTION INDICATED (OAI)
AUROBINDO PHARMA - US FDA INSPECTED EUGIA UNIT-III FROM JAN 27 TO FEB 6, 2026 WITH 11 OBSERVATIONS
Source text: ID:nNSE4MQDjD
Further company coverage: ARBN.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11